Vergelijking

Pasireotid vs. Selank

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

396091-73-9

129954-34-3

Molecuulmassa

1047.21 g/mol

751.85 g/mol

Halfwaardetijd

geen gegevens

0.3 h

Sequentie

geen gegevens

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Werkingsmechanisme

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Selank

Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.

Bewijsbasis

Hoogste bewijs

Humane RCT

Humane studie

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Pasireotid	Selank
Duitsland	Op recept	Niet goedgekeurd
RU	—	Op recept
Verenigde Staten	Op recept	Niet goedgekeurd

Volledige vermeldingen

Pasireotid

Volledige vermelding →

Selank

Volledige vermelding →

Frequently asked questions

What is the difference between Pasireotid and Selank?: Pasireotid is classified as "Onderzoek (overig)", while Selank is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Selank?: The highest available evidence level is "Humane RCT" for Pasireotid and "Humane studie" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Selank in Germany and the United States?: Duitsland: Pasireotid — Op recept, Selank — Niet goedgekeurd. Verenigde Staten: Pasireotid — Op recept, Selank — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Selank

Duitsland

Op recept

Niet goedgekeurd

—

Op recept

Verenigde Staten

Op recept

Niet goedgekeurd

Frequently asked questions

What is the difference between Pasireotid and Selank?

Pasireotid is classified as "Onderzoek (overig)", while Selank is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Selank?

The highest available evidence level is "Humane RCT" for Pasireotid and "Humane studie" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Selank in Germany and the United States?

Duitsland: Pasireotid — Op recept, Selank — Niet goedgekeurd. Verenigde Staten: Pasireotid — Op recept, Selank — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.